The Industrial Structure of Bio-Pharmaceutical Industry
Projected Based on Quantitative Analysis
DOI:
https://doi.org/10.51094/jxiv.771Keywords:
Industrial Structure, Bio-Pharmaceutical Industry, difference with low-molecular drug, quantitative analysisAbstract
We try to quantify numerical variation across biopharmaceutical companies in terms of their patent acquisition activities. We collected patent data for six companies from 1971 to 2012. Our patent data is classified into six categories: new antibodies, antibody optimization, formulation, manufacturing, other underlying technologies, and antibody products. A principal component analysis finds three major components. The first component is an overall bio-patent activity. This characteristic is often observed in many bio-ventures. The second component reflects the tendency towards more patents on antibody product than patents on new antibodies or optimization. This characteristic is observed in large biopharmaceutical companies. The third is the tendency towards the formulation and manufacturing. This feature can be seen in very limited number of firms, and characterizes the bio industry market.
Conflicts of Interest Disclosure
The authors declare no conflicts of interest associated with this manuscript. The authors have no conflicts of interest directly relevant to the content of this article.Downloads *Displays the aggregated results up to the previous day.
References
Bianchi, M., Cavaliere, A., Chiaroni, D., Frattini, F., & Chiesa, V. (2011). Organisational modes for open innovation in the bio-pharmaceutical industry: An exploratory analysis. Technovation, 31(1), 22-33. https://www.sciencedirect.com/science/article/pii/S0166497210000337
Binder, G., & Bashe, P. (2008). Science lessons: What the business of biotech taught me about management. Harvard Business School Press.
Cockburn, I. M., & Henderson, R. M. (2001). Scale and scope in drug development: Unpacking the advantages of size in pharmaceutical research. Journal of Health Economics, 20 (6), 1033–1057. https://www.sciencedirect.com/science/article/pii/S0167629601001084
Comanor, W. S. (1965). Research and technical change in the pharmaceutical industry. Review of Economics and Statistics, 47 (2), 182–190. https://www.jstor.org/stable/1924065
Gambardella, A. (1992). Competitive advantages from in-house scientific research: The US pharmaceutical industry in the 1980s. Research Policy, 21 (5), 391–407. https://www.sciencedirect.com/science/article/abs/pii/004873339290001K
Graves, S. B., & Langowitz, N. S. (1993). Innovative productivity and returns to scale in the pharmaceutical industry. Strategic Management Journal, 14 (8), 593–605.
Gassmann, O., Enkel, E., & Chesbrough, H. (2010). The future of open innovation. R&D Management, 40(3), 213-221. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1467-9310.2010.00605.x
Henderson, R., & Cockburn, I. (1996). Scale, scope and spillovers: the determinants of research productivity in drug discovery. RAND Journal of Economics, 27 (1), 32–59. https://www.nber.org/papers/w4466
Hughes, S. S. (2011). Genentech: The beginnings of biotech. University of Chicago Press.
Jensen, E. J. (1987). Research expenditures and the discovery of new drugs. Journal of Industrial Economics, 36 (1), 83–95. https://www.jstor.org/stable/2098598
Kokubo, K. (2017). Hirenzoku inobesyon heno kai: kenkyukaihatsugata sangyo no R&D seisansei koujou no kagi [Solution for pharmaceutical disruptive innovation : Key of improving R&D efficiency]. Hakutou-shobo (in Japanese).
Kuwashima, K. (2006). Fukakujitsusei no manejimento: shinyaku soushutsu no kai [Management of uncertainty: Solution for pharmaceutical R&D management]. Nikkei BP (in Japanese).
Miyashige, T., & Fujii, A. (2014). Iyakuhin kigyou no kenkyu kaihatsu senryaku: Bunri suru kenkyu kaihatsu to baio gijyutsu no taitou [Strategic R&D of pharmaceutical companies: Emerging biotechnology and diverging R&D processes]. Keibun-sha (in Japanese).
Odagiri, H., & Murakami, N. (1992). Private and quasi-social rates of return on pharmaceutical R&D in Japan. Research Policy, 21 (4), 335–345. https://www.sciencedirect.com/science/article/abs/pii/004873339290032Y
Schwartzman, D. (1976). Innovation in the pharmaceutical industry. Johns Hopkins University Press.
Vernon, J. M., & Gusen, P. (1974). Technical change and firm size: the pharmaceutical industry. Review of Economics and Statistics, 56 (3), 294–302.
Downloads
Posted
Submitted: 2024-06-25 08:20:23 UTC
Published: 2024-07-01 01:08:22 UTC
License
Copyright (c) 2024
Tetsuya Miyashige
Atsushi Fujii
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
